Ovid Therapeutics
OVID
OVID
49 hedge funds and large institutions have $77.2M invested in Ovid Therapeutics in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
+7
Holders Change %
+16.67%
% of All Funds
1.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
18
Reduced
10
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$6.64M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$3.68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.7M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$484K |
| 5 |
Morgan Stanley
New York
|
+$196K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.69M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.37M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.23M |
| 4 |
Jennison Associates
New York
|
-$883K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$833K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
CI
51
Cowen Inc
New York
| – | -$88K | -10,211 | Closed |
|
|
NFA
52
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$25K | -2,879 | Closed |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -329 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$2K | -246 | Closed |
|